All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Quality of life (MLHFQ): from 0 to 105 · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
Serious adverse events · children with sickle cell anaemia and microalbuminuria
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality due to any cause · children with sickle cell anaemia and microalbuminuria
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · children with sickle cell anaemia and microalbuminuria
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reduction or prevention of kidney disease progression · people with sickle cell disease
1 finding from 1 review
Serious adverse events · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reduction or prevention of kidney disease progression · children with sickle cell anaemia and microalbuminuria
1 finding from 1 review
Migraine frequency Number of attacks · primary Raynaud's phenomenon
1 finding from 1 review
Severity of attacks · primary Raynaud's phenomenon
1 finding from 1 review
Duration of attacks · primary Raynaud's phenomenon
1 finding from 1 review
QoL · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (4 to 6‐week · primary Raynaud's phenomenon
Angiotensin‐converting enzyme inhibitors showed no clear difference in adverse events (4 to 6‐week compared with placebo (low certainty).
1 finding from 1 review
RCS · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (all causes) · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors showed no clear difference in all‐cause death Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with diabetes and kidney disease
It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes cardiovascular death Median compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Doubling of SCr Median · people with diabetes and kidney disease
It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes doubling of SCr Median compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors showed no clear difference in fatal or nonfatal stroke Median compared with placebo or no treatment (low certainty).
1 finding from 1 review